Pulse steroid injection for treating difficult rheumatoid arthritis
Revealing the Potential of Intravenous Pulse Steroid Therapy; Impressive Results in Attaining Remission or Low Disease Activity in Refractory Rheumatoid Arthritis
This study is testing if pulse steroid injections can help people with tough-to-treat rheumatoid arthritis feel better and achieve lower disease activity.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 268 (estimated) |
| Ages | 20 Years to 65 Years |
| Sex | All |
| Sponsor | Sohag University Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT06456489 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of pulse steroid injections using Solumedrol in patients with refractory rheumatoid arthritis. Participants will be assessed for disease activity using the Disease Activity Score (DAS28) and American College of Rheumatology (ACR) criteria at baseline and monthly for three months. The goal is to determine if this treatment can lead to remission or low disease activity in these patients. The study is interventional and is in Phase 3, indicating a focus on confirming effectiveness and monitoring side effects.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with refractory rheumatoid arthritis who have not responded adequately to standard treatments.
Not a fit: Patients with other connective tissue diseases or endocrine disorders such as diabetes and thyroid issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve the quality of life for patients with refractory rheumatoid arthritis by achieving remission or low disease activity.
How similar studies have performed: Other studies have shown promise with steroid injections in managing rheumatoid arthritis, but this specific approach may offer novel insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Refractory rheumatoid arthritis patients Exclusion Criteria: * Other connective tissue diseases * Endocrine diseases such as DM and thyroid disorders
Where this trial is running
Cairo
- Al-Azhar Univrsity — Cairo, Egypt (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.